Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2020

View Archived Issues

Comprehensive look identifies insulin autoantigens

Versatope selects VT-105 influenza vaccine candidate for clinical development

AI-guided discovery of potent and selective oral p300/CBP histone acetyltransferases inhibitors

Expression of broadly neutralizing anti-HIV Abs by aerosol delivery of synthetic mRNA to the vagina

Cadent opens phase II study of CAD-1883 for spinocerebellar ataxia

Grant supports Bloom's development of microbiota-based therapies for ALS

Algernon supports phase II study of ifenprodil for coronavirus infection

First patient dosed in phase II study of nNK cells for the treatment of MCC

Researchers identify miRNAs associated with NAFLD in adolescents with obesity

Almonertinib receives approval in China for EGFR T790M-mutant NSCLC

Phosphatidylinositol 3-kinase inhibitors disclosed by BeiGene

Shanghai Institute of Materia Medica, Shaoxing Zeroin Biomedicines patent TREK-1 blockers

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery describe drugs targeting CRBN

Roivant seeks to advance development of gimsilumab for COVID-19-related ARDS

New IRAK-4 inhibitors identified at Zhejiang Hisun Pharmaceutical

Shanghai Maxinovel Pharmaceuticals synthesizes new adenosine A2A receptor antagonists

Positive topline data for pivotal phase III FLASH study of SGX-301

Aqualung Therapeutics advances development of ALT-100 for ARDS and VILI

Phase I data reported for BI-836826 in NHL

Desmopressin shows promise for the management of bleeding in rectal cancer

Targeting glycosylated PD-1 induces potent antitumor immunity

FDA approves Epclusa for pediatric patients with hepatitis C

Polarisqb partners with Fujitsu on drug discovery

Lexicon announces early close-out of long-term outcome studies of sotagliflozin

Promising data reported on favipiravir for COVID-19 in China

Ridgeback and DRIVE partner to develop EIDD-2801 for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...